Diaceutics PLC - Issue of Share Options / PDMR Shareholdings
1 April 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 871,411 share options over ordinary shares of
Share Options were granted as follows:
|
Name |
Number of Share Options granted |
Total no. of ordinary shares under option post grant |
% of existing issued share capital |
Effective Grant date |
|
|
79,303 |
332,845 |
0.40% |
|
|
|
41,838 |
41,838 |
0.05% |
|
|
|
72,290 |
316,444 |
0.38% |
|
|
|
51,938 |
51,938 |
0.06% |
|
|
|
50,495 |
50,495 |
0.06% |
|
|
Susanne Munksted, CPO and PDMR |
50,953 |
174,075 |
0.21% |
|
|
|
48,463 |
81,722 |
0.10% |
|
|
Other employees (34 persons) |
476,131 |
1,095,823 |
1.30% |
|
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, including any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to
Following this grant, the total number of share options outstanding in the Company is 3,191,161, representing approximately 3.80% of its current issued share capital of 84,063,923.
Enquiries:
|
Diaceutics PLC |
|
|
|
Via Alma PR |
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) |
Tel: +44 (0)20 7710 7600 |
|
|
|
|
|
|
|
Alma PR |
Tel: +44(0)20 3405 0205 |
|
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
|
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
CEO, Director |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
79,303 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
|
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
CFO, Director |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
41,838 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
|
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
CIO, Director |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
72,290 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
|
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
COO and PDMR |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
51,938 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
|
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
CCO and PDMR |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
50,495 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
Susanne Munksted |
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
CPO and PDMR |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
50,953 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
|
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
CGO and PDMR |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Options over new ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Grant of share options |
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
Exercise price of 0.2p per share |
48,463 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
|
|||||
|
f. |
Place of the transaction |
Outside a trading venue |
|||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE